Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of “Moderate Buy” from Analysts

Sutro Biopharma, Inc. (NASDAQ:STRO) has been given an average recommendation of “Moderate Buy” by the eight analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $11.13.

A number of research firms have weighed in on STRO. Piper Sandler reiterated an “overweight” rating and issued a $11.00 price target on shares of Sutro Biopharma in a research report on Friday, October 11th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Sutro Biopharma in a report on Monday, November 18th. JMP Securities reissued a “market outperform” rating and set a $17.00 price target on shares of Sutro Biopharma in a report on Wednesday, December 11th. Wells Fargo & Company lowered their price objective on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research report on Wednesday, December 11th. Finally, Wedbush reiterated an “outperform” rating and set a $8.00 target price on shares of Sutro Biopharma in a research report on Tuesday, December 10th.

Sutro Biopharma Trading Up 3.3 %

Shares of NASDAQ:STRO opened at $1.88 on Monday. The stock has a 50 day moving average of $3.10 and a 200 day moving average of $3.54. The company has a market cap of $155.02 million, a PE ratio of -1.17 and a beta of 1.09. Sutro Biopharma has a 12-month low of $1.70 and a 12-month high of $6.13.

Hedge Funds Weigh In On Sutro Biopharma

Institutional investors have recently added to or reduced their stakes in the company. Gladius Capital Management LP purchased a new stake in shares of Sutro Biopharma during the 3rd quarter valued at about $28,000. ProShare Advisors LLC raised its position in Sutro Biopharma by 49.1% during the second quarter. ProShare Advisors LLC now owns 16,316 shares of the company’s stock valued at $48,000 after purchasing an additional 5,373 shares during the period. Virtu Financial LLC bought a new stake in shares of Sutro Biopharma in the 3rd quarter valued at approximately $77,000. Intech Investment Management LLC purchased a new position in shares of Sutro Biopharma in the 3rd quarter worth approximately $91,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Sutro Biopharma by 27.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,943 shares of the company’s stock worth $97,000 after purchasing an additional 7,082 shares during the period. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.